Navigation Links
LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
Date:4/20/2009

COPENHAGEN, April 20 /PRNewswire/ -- Santaris Pharma announced today promising findings on the in vitro and in vivo activity of microRNA-targeted therapeutics against cancer developed on the basis of its proprietary Locked Nucleic Acid (LNA) Drug Platform. In both in vitro and in vivo models Santaris Pharma's cancer targeted LNA-antimiR(R)'s demonstrated outstanding recognition and inhibition of disease-associated microRNAs due to their high specificity and affinity. The findings were presented this week at the AACR Meeting in Colorado at a symposium on microRNAs and human cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Santaris Pharma has made significant progress in advancing a rich pipeline of clinical and preclinical drug candidates targeting disease related RNAs, including microRNAs," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer. "These results are another demonstration of the fact that our small, single-stranded oligonucleotides have great potential in relation to the development of microRNA targeting therapeutics within a range of disease areas."

Santaris Pharma is a leader within microRNA research and is collaborating with scientists world-wide to exploit the advantages of the LNA chemistry to design and develop effective and safe antimiRs against a broad range of diseases, including cancer.

Santaris Pharma (founded in 2003) is a privately held clinical stage biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and up-front payments.

    For further information please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com
   http://www.santaris.com


'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
2. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. TauTaTis Discovers Potent Inhibitor of Parkinsons Disease Gene Activity
5. Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
6. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
7. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
8. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
9. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
10. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
11. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... New FDA action date of July 22, ... July 22, 2016   --> - ... - Lifitegrast has the potential to be the only ... signs and symptoms of dry eye disease in adults --> ... approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):